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The X-ray structure of the enzyme 5-aminolaevulinic acid
dehydratase (ALAD) from yeast complexed with the
competitive inhibitor 5-hydroxylaevulinic acid has been
determined at a resolution of 1.9 A˚. The structure shows that
the inhibitor is bound by a Schiff-base link to one of the
invariant active-site lysine residues (Lys263). The inhibitor
appears to bind in two well defined conformations and the
interactions made by it suggest that it is a very close analogue
of the substrate 5-aminolaevulinic acid (ALA).
1. Introduction
The enzyme 5-aminolaevulinic acid dehydratase (ALAD, also
known as porphobilinogen synthase; EC 4.2.1.24) catalyses an
early step in the biosynthesis of tetrapyrroles involving the
condensation of two 5-aminolaevulinic acid (ALA) molecules
to form the pyrrole porphobilinogen (PBG; see Fig. 1; Jordan,
1991, 1994; Warren & Scott, 1990; Jaffe, 1995, 2003). Subse-
quent enzymes in the pathway cyclize four of these PBG
molecules to make the core tetrapyrrole framework uro-
porphyrinogen III, which undergoes various modifications to
form a variety of essential metallo-prosthetic groups, including
haem, chlorophyll and the cobalamins. ALAD enzymes share
a high degree of sequence identity, contain about 350 amino
acids per subunit and are usually octameric. In humans,
hereditary deficiencies in ALAD give rise to the rare disease
Doss porphyria (Doss et al., 1979) and the exquisite sensitivity
of the human enzyme to inhibition by lead ions is a major
causative factor in acute lead poisoning (Simons, 1995; Warren
et al., 1998).
The X-ray structures of ALADs from several species have
been determined and several inhibitor complexes have been
studied (Erskine, Senior, Awan et al., 1997; Erskine, Newbold
et al., 1999, 2001; Erskine, Norton et al., 1999; Frankenberg et
al., 1999; Mills-Davies, 2001; Erskine, Coates et al., 2001). In
these structures, the enzyme is a homo-octamer with each
Figure 1
The reaction catalysed by 5-aminolaevulinic acid dehydratase (ALAD).
Two molecules of 5-aminolaevulinic acid (ALA) are condensed to form
the pyrrole porphobilinogen (PBG).
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subunit adopting a (/)8 or TIM-barrel fold with an N-
terminal arm which in yeast ALAD is 39 residues in length
(Fig. 2). Within the octamer, subunits form dimers in which
each subunit has its N-terminal arm wrapped around the
barrel of the other monomer. The octamers result from side-
by-side packing of the closely associated dimers, giving a
quaternary structure in which all eight active sites are oriented
towards the outer surface and are independent. The active site
of each subunit is located in a pronounced cavity formed by
loops at the C-terminal ends of the -strands forming the TIM
barrel. Recently, evidence has been found for hexameric
quaternary forms of some ALADs (Breinig et al., 2003;
Bollivar et al., 2004).
At the base of the active site are two lysine residues (210
and 263 in yeast ALAD), one of which (Lys263) is known to
form a Schiff-base link to the first molecule of substrate that
binds to the active site (Jordan & Gibbs, 1985; Gibbs &
Jordan, 1986). Single-turnover experiments with labelled
ALA have shown that the substrate bound to Lys263 is
incorporated into the propionic acid side, or P-side, of the
product PBG, whereas the second substrate molecule forms
the acetic acid side, or A-side, of PBG (see Fig. 1). Thus,
catalysis was shown to proceed by formation of a Schiff-base
link at the P-site between the 4-keto group of substrate ALA
and an invariant lysine residue, equivalent to Lys263 in yeast
ALAD.
Recently, the structures of several ALADs complexed with
the inhibitors 4,7-dioxosebacic acid and 5-fluorolaevulinic
have been solved at high resolution (Erskine, Coates et al.,
2001; Kervinen et al., 2001; Fre`re et al., 2002). Intriguingly,
these inhibitors form two Schiff bases at the active site
involving Lys210 as well as Lys263 in yeast ALAD numbering.
The structural evidence that both invariant lysines form Schiff
bases with some inhibitors suggests that catalysis involves a
double Schiff-base mechanism.
In many ALADs, an active-site zinc ion has been implicated
in the catalytic mechanism and is thought to act on substrate
bound to the A-site. The zinc-binding site is formed by the
following residues in yeast ALAD: Cys133, Cys135 and
Cys143. In contrast, plant and some bacterial ALADs require
magnesium and lack the triple-cysteine sequence motif, which
is replaced by other amino acids (predominantly aspartate
residues) that were thought likely to coordinate an active-site
magnesium ion (Boese et al., 1991). However, no electron
density for an active-site magnesium has been found in crystal
structures of several of these ALADs (Frankenberg et al.,
1999; Coates et al., 2004) and there is evidence that the enzyme
Table 1
Statistics for entire data set.
Resolution range (A˚) 44.3–1.9 (2.0–1.9)
Rmerge (%) 5.8 (41.9)
Completeness (%) 100.0 (100.0)
Multiplicity 11.9 (10.0)
Mean I/(I) 24.1 (6.1)
Fraction I > 3(I) (%) 84.1
Refinement
R factor (%) 18.95
Rfree (%) 24.93
No. of reflections 35723
R.m.s.d.s (A˚)
Bond lengths 0.004
1–3 distances 0.012
Bumps 0.031
Chiral tetrahedra 0.007
Main-chain planes 0.012
Side-chain planes 0.009
Figure 2
(a) A ribbon diagram of the TIM-barrel fold of the ALAD monomer with its pronounced N-terminal arm and two active-site lysines shown in ball-and-
stick representation. (b) The assembly of ALAD monomers (coloured differently) to form dimers and (c) the organization of the functional ALAD
octamer. This figure and others similar were prepared using the programs MOLSCRIPT (Kraulis, 1991) and BOBSCRIPT (Esnouf, 1997).
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from some species is completely metal-independent (Bollivar
et al., 2004). Thus, it is likely that any apparent magnesium
dependence probably arises from the enzyme’s allosteric
metal-binding site at the subunit interface, which was first
characterized in the Escherichia coli enzyme (Erskine, Norton
et al., 1999). A more detailed description of the metal
requirement of ALADs is given in Jaffe (2003).
We have analysed the structures of ALADs in which the
active site is occupied by various inhibitors and all were found
to form a Schiff base with Lys263 (Erskine, Newbold et al.,
2001). In addition, the structure of substrate (ALA) bound in
this site has been determined (Erskine, Newbold et al., 2001).
The structure of this complex was obtained by crystallizing
partially purified yeast ALAD and ALA was found to be
covalently bound as a Schiff base to Lys263 at the P-site. The
structure of a putative intermediate resembling covalently
bound product has also been determined by co-crystallizing
the yeast enzyme in the presence of added substrate ALA
(Erskine et al., 2003). We now report on the high-resolution
X-ray structure of the inhibitor 5-hydroxylaevulinic acid
(Fig. 3), which is a close analogue of the substrate ALA,
bound to the yeast ALAD enzyme.
2. Materials and methods
Recombinant yeast ALAD was expressed and purified as
described previously (Senior et al., 1996; Erskine, Senior,
Awan et al., 1997). Crystals of yeast ALAD with 5-hydroxy-
laevulinic acid bound were obtained by co-crystallizing the
enzyme in the presence of the inhibitor. The hanging-drop
vapour-diffusion method was used with 5-hydroxylaevulinic
acid present at a concentration of 10 mM and enzyme present
at a concentration of 2 mg ml1. Apart from the presence of
inhibitor, the crystallization conditions (2–10% PEG 6000,
200 mM Tris–HCl pH range 7.0–8.0, 6 mM -mercaptoethanol
and 70 mM zinc sulfate) are otherwise identical with those
used to crystallize the native enzyme (Erskine, Senior,
Maignan et al., 1997). Crystals of the complex, which appeared
within 3–4 weeks, belong to space group I422, with unit-cell
parameters a = b = 102.6, c = 168.4 A˚. The crystals were flash-
cooled in liquid ethane and X-ray data were collected at ESRF
(Grenoble) using the ID29 beamline with the crystal main-
tained at a temperature of 100 K using an Oxford Cryosystems
cooler. The data were processed using MOSFLM (Leslie,
1992) and the CCP4 suite (Collaborative Computational
Project, Number 4, 1994). The structure was refined using
SHELX (Sheldrick & Schneider, 1997) and the program
RESTRAIN (Haneef et al., 1985) was used for refinement of
translation–libration–screw (TLS) tensors. Graphical
rebuilding was performed using TURBO-FRODO (Bio-
Graphics, Marseille, France) running on Silicon Graphics
(SGI) computers.
3. Results and discussion
5-Hydroxylaevulinic acid (Fig. 3) is a competitive inhibitor of
ALAD enzymes, typically with Ki values of 0.25 mM (Neier,
1997). The initial difference map for yeast ALAD co-crystal-
lized with 5-hydroxylaevulinic acid showed convincing elec-
tron density for the inhibitor bound as a Schiff-base complex
with one of the invariant active-site lysines (Lys263) in the
P-site of the enzyme. The ligand was built into the density
accordingly and the structure of the complex refined for
several cycles after each round of manual rebuilding. The final
electron-density map at a resolution of 1.9 A˚ is shown in
Fig. 4(a), where it can be seen that the inhibitor adopts two
conformations on binding to the enzyme. This interpretation
was partly based on the finding that most inhibitor complexes
of yeast ALAD analysed previously at high resolution were
found to exhibit similar disorder in the bound conformation of
the inhibitor itself and the side chain of Lys263 to which the
inhibitors are attached (Erskine, Newbold et al., 2001).
Evidence for the occurrence of two conformations was
provided by refining the structure with the inhibitor built in
one conformer alone, which yielded strong positive difference
density for the other conformer (see Fig. 4b). Refinement of
the occupancy of the two conformers yielded values of 52 and
48%, suggesting that the inhibitor binds with equal preference
for both of the conformations. The atoms of the bound inhi-
bitor have a mean isotropic B factor of 44.9 A˚2, which is
comparable with the B factors of the entire complex (mean
Biso = 49.27 A˚
2), confirming that the inhibitor has bound to the
majority of the enzyme molecules forming the crystal. This
presumably reflects the buried state of the inhibitor, which is
covered by the enzyme’s active-site flap (residues 215–235).
These B factors appear to be rather high for a structure refined
at 1.9 A˚ resolution and we presume that this is an effect of the
TLS refinement, since lower values were obtained when the
structure was refined by conventional means only, e.g. the
mean Biso for the complex was 39.6 A˚
2, a value which is closer
to the Wilson plot B factor of 33.5 A˚2.
The electron density for the inhibitor is good except for the
C-2 position: an effect common to other P-site ligands which
exhibit disordered binding, e.g. the substrate ALA and
laevulinic acid (Erskine, Newbold et al., 1999, 2001; Erskine,
Coates et al., 2001). The electron density for the amino acids
surrounding the inhibitor in the P-site is very good. In
contrast, a number of the amino-acid side chains making up
the unoccupied A-site have much poorer electron density.
However, it has been shown that these become dramatically
more ordered in the presence of inhibitors which occupy the
A-site, e.g. 4,7-dioxosebacic acid (Erskine, Coates et al., 2001).
Figure 3
The chemical formula of the ALAD inhibitor 5-hydroxylaevulinic acid.
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The final structure, which was refined using data between
44.3 and 1.9 A˚, has an R factor of 18.95% and an Rfree of
24.93% (see Table 1). Refinement of the TLS tensors for the
TIM-barrel and arm domains gave a significant improvement
in Rfree of over 8%. The final structure has 89.7% of its resi-
dues within the ‘most favoured’ regions of the Ramachandran
plot by the PROCHECK criteria (Laskowski et al., 1993) and
9.6% of residues within the so-called ‘additional allowed’
boundary. No residues are in the disallowed regions. The
temperature factors are reasonable except for a few residues
in the active-site flap (most notably 228–230), where the
electron density remains poor despite extensive efforts to
rebuild these residues throughout the refinement process.
Nonetheless, the electron density for the active-site loop in
this complex is substantially better than that of the native
enzyme.
The active site of ALAD is located in a large cavity at the
C-terminal end of the eight-stranded all-parallel -barrel. It
involves two invariant lysine residues (263 and 210 in yeast
ALAD), as well as a zinc ion which is coordinated by three
cysteine residues numbered 133, 135 and 143 in the yeast
enzyme. The inhibitor in this study forms a Schiff base with
Lys263 and is held in the P-site of the enzyme. The C-5
hydroxyl group of the inhibitor forms a strong hydrogen bond
with the —NH2 side chain of the other invariant active-site
lysine (Lys210) in one conformer. Whilst the inhibitor appears
to bind in two conformations in the P-site, in both of these
conformers the C-5 hydroxyl group interacts with the side
chains of Asp131 and Ser179, which are strongly conserved
and have been implicated in the mechanism by site-directed
mutagenesis (Shoolingin-Jordan et al., 2002). The same inter-
actions have been observed for the C-5 amino group of
substrate ALA when bound to the P-site of the enzyme
(Erskine, Newbold et al., 2001). The C-5 hydroxyl group also
forms a hydrogen bond to the water molecule datively bound
to the active-site zinc ion and the C-5 amino group of substrate
ALA likewise also forms this interaction (Erskine, Newbold et
al., 2001). The aliphatic parts of the inhibitor and substrate
ALA (C-2 to C-5) reside in a hydrophobic pocket formed
mainly by aromatic side chains of residues Phe89, Tyr216,
Phe219, Tyr287 and Val289. Like ALA, the C-1 carboxyl
group of hydroxylaevulinic acid forms hydrogen bonds with
the side chains of Ser290 and Tyr329 in both of the bound
conformers. Other hydrogen bonds are formed with the side
chain of Tyr287 and the main-chain NH of Ser290 in one of the
conformers only.
The A-site in this complex is a solvent-filled cavity bounded
on one side by the P-site 5-hydroxylaevulinic acid molecule
and on the other by two arginine residues (220 and 232) which
are strongly conserved and are thought to interact with the
Figure 4
(a) The structure of the inhibitor 5-hydroxylaevulinic acid (labelled OHLA) bound in two conformations to one of the active-site lysines (Lys263) of
yeast ALAD. The structure has been refined at 1.9 A˚ resolution and the corresponding electron density, contoured at 1.0 r.m.s., is shown as purple lines.
The active-site zinc ion is shown on the lower right. (b) The same view of the bound inhibitor but showing only one conformation and the resulting
positive difference density contoured at 4.5 r.m.s. (shown in magenta) indicating the presence of the other conformer.
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carboxyl of A-side substrate. Evidence for this was provided
by bound structures of the inhibitors 4,7-dioxosebacic acid and
5-fluorolaevulinic acid, which occupy the A-site and P-site
(Erskine, Coates et al., 2001; Kervinen et al., 2001; Fre`re et al.,
2002). A major part of the A-site is formed by the zinc ion held
by the side chains of three cysteines. As mentioned above,
there is a solvent molecule bound to the zinc ion that is within
hydrogen-bonding distance of the amino group of P-side
ALA. It has been speculated that this solvent molecule may
actually be a zinc-bound hydroxide which abstracts a proton
from C-3 of A-side ALA as a prerequisite for formation of the
C—C bond between the two substrates (Erskine, Norton et al.,
1999).
The current study shows that 5-hydroxylaevulinic acid
appears in structural terms to be an exceptionally good
analogue of the substrate ALA; both bind by making almost
exactly the same interactions. The fact that the C-5 hydroxyl
binds in the same position as the C-5 amino group of ALA
suggests that the charge of the C-5 substituent does not have a
great effect on its binding mode. The lower polarity of the
hydroxylaevulinic acid compared with substrate ALA might
also be expected to increase its bio-availability as an inhibitor
of tetrapyrrole biosynthesis, possibly with in vivo applications.
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